U.S. Digital Therapeutics Market to Reach $21.46B by 2030

The U.S. digital therapeutics market is set to experience remarkable growth, projected to reach $21.46 billion by 2030 with a CAGR of 33.8% from 2023 to 2030, according to a report by Coherent Market Insights, Inc. 

Digital therapeutic solutions are recognised for their ability to enhance medication adherence and facilitate long-term behaviour change in patients with chronic conditions. The report emphasises that government initiatives to digitalise healthcare will be crucial in driving market expansion. 

Digital therapeutics, driven by high-quality software programs, aim to prevent, manage, and treat medical disorders, providing personalised support and improving access to safe and effective treatments. 

The report highlights the dominance of the treatment and disease management sector, attributing it to the growing disease burden and demand for reliable therapies. The healthcare providers segment is expected to lead the market due to increased digitalisation in the industry and the adoption of digital healthcare solutions. 

Key U.S. digital therapeutics market players include 2Morrow, ResMed, Omada Health, Teladoc, Lark, Kaia Health, Fitbit, Cognoa, and Akili Interactive Labs. However, challenges such as vulnerability to third-party interference and data loss from signal errors and transmission outages need to be addressed to ensure the sustained growth of the digital therapeutics market.